Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:BOLD NASDAQ:ELUT NASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$3.65+3.8%$3.10$1.60▼$15.04$99.37M1.9183,860 shs36,319 shsBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.74M-1.2271,156 shs96,520 shsELUTElutia$1.88-6.5%$2.10$1.61▼$5.12$79.70M0.8944,111 shs202,022 shsPREPrenetics Global$8.09+1.0%$7.89$3.09▼$11.99$105.05M0.1540,127 shs16,208 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience0.00%-1.62%+19.12%+41.83%-72.80%BOLDBoundless Bio0.00%+1.79%-0.44%-2.98%-66.17%ELUTElutia0.00%-17.54%-5.05%-1.05%-53.00%PREPrenetics Global0.00%+6.31%+1.25%-2.76%+73.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$3.65+3.8%$3.10$1.60▼$15.04$99.37M1.9183,860 shs36,319 shsBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.74M-1.2271,156 shs96,520 shsELUTElutia$1.88-6.5%$2.10$1.61▼$5.12$79.70M0.8944,111 shs202,022 shsPREPrenetics Global$8.09+1.0%$7.89$3.09▼$11.99$105.05M0.1540,127 shs16,208 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience0.00%-1.62%+19.12%+41.83%-72.80%BOLDBoundless Bio0.00%+1.79%-0.44%-2.98%-66.17%ELUTElutia0.00%-17.54%-5.05%-1.05%-53.00%PREPrenetics Global0.00%+6.31%+1.25%-2.76%+73.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.57Moderate Buy$8.50133.20% UpsideBOLDBoundless Bio 2.25Hold$3.50207.02% UpsideELUTElutia 3.00Buy$8.00325.53% UpsidePREPrenetics Global 3.00Buy$9.0011.25% UpsideCurrent Analyst Ratings BreakdownLatest BOLD, ANRO, PRE, and ELUT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/11/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.006/26/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/ABOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/AELUTElutia$24.38M3.27N/AN/A($1.31) per share-1.44PREPrenetics Global$30.62M3.43N/AN/A$13.20 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)BOLDBoundless Bio-$65.36MN/AN/AN/AN/AN/A-44.79%-34.24%N/AELUTElutia-$53.95M-$1.06N/AN/AN/A-90.01%N/A-54.08%11/13/2025 (Estimated)PREPrenetics Global-$46.30M-$3.99N/AN/AN/A-115.91%-28.07%-22.27%10/6/2025 (Estimated)Latest BOLD, ANRO, PRE, and ELUT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELUTElutia-$0.17-$0.26-$0.09-$0.26$6.55 million$6.26 million8/13/2025Q2 2025ANROAlto Neuroscience-$0.57-$0.65-$0.08-$0.65N/AN/A8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/A6/12/2025Q1 2025PREPrenetics GlobalN/A-$0.80N/A-$0.80N/A$17.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1818.4318.43BOLDBoundless Bio0.3914.0814.08ELUTElutiaN/A0.590.45PREPrenetics GlobalN/A2.071.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/ABOLDBoundless BioN/AELUTElutia74.03%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.13%BOLDBoundless Bio21.10%ELUTElutia27.60%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A27.08 million24.06 millionN/ABOLDBoundless Bio20722.39 million17.66 millionNo DataELUTElutia18042.40 million30.69 millionNot OptionablePREPrenetics Global112.98 million11.97 millionNot OptionableBOLD, ANRO, PRE, and ELUT HeadlinesRecent News About These CompaniesBeckham's IM8 AI Ad Promotes 'The Best'September 3, 2025 | mediapost.comMPrenetics Global Divests ACT Genomics Stake and Invests in BitcoinAugust 22, 2025 | tipranks.comPrenetics Global (NASDAQ:PRE) Trading Up 1.8% - Should You Buy?August 21, 2025 | marketbeat.comPrenetics Approves Major Share Capital Increase at August 2025 MeetingAugust 1, 2025 | tipranks.comPrenetics Global Limited (PRE) Earnings Surprise Summary (EPS ...July 25, 2025 | seekingalpha.comPrenetics Global Limited Adopts Bitcoin Treasury Strategy Amidst Market VolatilityJuly 17, 2025 | tipranks.comPRE Prenetics Global Limited - Seeking AlphaJuly 9, 2025 | seekingalpha.comPrenetics Global Limited (PRE) - Yahoo FinanceJune 30, 2025 | finance.yahoo.comAryna Sabalenka Adds Her Muscle to IM8 as Ambassador & ShareholderJune 30, 2025 | msn.comAryna Sabalenka Becomes First Current Athlete Shareholder in Prenetics' IM8 Supplements BrandJune 26, 2025 | quiverquant.comQWorld No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and ShareholderJune 26, 2025 | globenewswire.comCardone Capital goes all-in on Bitcoin adding 1K BTC to its reserveJune 23, 2025 | msn.com$1.24 Billion in Bitcoin Added to Corporate Treasuries This WeekJune 22, 2025 | coingape.comCA South Korean Biotech Firms Gets $183.3M Funding to Build Bitcoin TreasuryJune 21, 2025 | coindesk.comHealthcare Meets Crypto: David Beckham–Backed Prenetics Launches $20M Bitcoin TreasuryJune 20, 2025 | techstory.inTPrenetics Global (NASDAQ:PRE) Stock, Short Interest ReportJune 19, 2025 | benzinga.comPrenetics Adopts $20M Bitcoin Treasury StrategyJune 19, 2025 | thecurrencyanalytics.comTPrenetics Global First Quarter 2025 Earnings: Revenues Beat Expectations, EPS In LineJune 19, 2025 | finance.yahoo.comPrenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to BoardJune 18, 2025 | globenewswire.comPrenetics Global Limited Divests ACT Genomics, Strengthens Financial Position and Raises FY2025 Revenue OutlookJune 18, 2025 | quiverquant.comQPrenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million TransactionJune 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Is Viking’s Growth Still Worth the Premium?By Chris Markoch | August 20, 2025D-Wave Buying Spree: Will These Firms Be Potential Targets?By Nathan Reiff | August 19, 2025Who Won and Who Lost in Nuclear Energy’s Q2 EarningsBy Leo Miller | August 20, 2025BOLD, ANRO, PRE, and ELUT Company DescriptionsAlto Neuroscience NYSE:ANRO$3.64 +0.14 (+3.85%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$3.67 +0.02 (+0.69%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Elutia NASDAQ:ELUT$1.88 -0.13 (-6.47%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 09/5/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Prenetics Global NASDAQ:PRE$8.09 +0.08 (+1.00%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$8.02 -0.07 (-0.87%) As of 09/5/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
